RxDoctor Payments Data

Judd Larowe, MD

Internal Medicine · Cody, WYNPI 1346239548

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 24.6% of the total. Reporting peaked in 2021 at $158 and has fallen 84.7% since, to $24 in 2025.

$541in general payments, 2019–2025

Across 30 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$133
  • Pacira Therapeutics, Inc.$73
  • Exact Sciences$64
  • Lilly USA, LLC$60
  • E.r. Squibb & Sons, L.L.C.$38
  • Amgen$36
  • plus $137 from 7 others

What the payments were for

  • Food & beverage$541100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$541 in reported general payments places this provider in the 85th percentile of 101 internal medicine providers in Wyoming.

See all internal medicine providers in Wyoming

Medicare billing

Part B allowed, 2024
$226,469
Medicare patients
512
Services billed
3,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide198$277,572
EliquisApixaban112$122,622
MounjaroTirzepatide39$46,743
XareltoRivaroxaban27$29,570
JardianceEmpagliflozin25$28,352
FarxigaDapagliflozin Propanediol29$27,800
TrulicityDulaglutide18$16,646
Emgality PenGalcanezumab-Gnlm13$8,462
Rosuvastatin Calcium353$4,533
SymbicortBudesonide/Formoterol Fumarate19$4,186
Metoprolol Succinate215$3,459
Levothyroxine Sodium316$2,973
Valsartan78$2,836
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen108$2,221
Omeprazole198$2,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$133$277,572198 claims
PfizerEliquis$31$122,622112 claims
Lilly USA, LLCMounjaro, Trulicity$60$63,38957 claims
Boehringer IngelheimJardiance$19$28,35225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 101 internal medicine providers in Wyoming.

Other internal medicine in Cody

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →